A REVIEW OF HEMGENIX

Quantity of eligible clients: CDEC reviewed the uncertainty in the amount of patients with reasonably serious to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some individuals who're labeled as possessing delicate or average condition can have a critical bleeding phenotype,